Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2010

View Archived Issues

Roche presents novel DP2 receptor antagonists

Boehringer Ingelheim presents novel 11-beta-HSD1 inhibitors

Takeda claims novel H+/K+-ATPase proton pump inhibitors

Boehringer Ingelheim claims new Mnk1 and/or Mnk2 inhibitors

Takeda identifies novel Polo-like kinase inhibitors

Vorinostat exhibits safety and tolerability in phase II trial in advanced renal cell carcinoma

Clinical phase I/II data on TAK-700 in metastatic CRPC disclosed

Chugai seeks Japanese approval for Herceptin in combination with Xeloda for gastric cancer

Cilengitide does not exhibit antitumor activity in phase II nonmetastatic CRPC trial

Paclitaxel nanoparticles potent as second-line therapy in phase II trial in metastatic UC

Tripep changes name to ChronTech Pharma

A.P. Pharma receives FDA complete response letter for APF-530

Cytokinetics opens phase IIa CK-2017357 trial in ALS

GlaxoSmithKline begins phase III Relovair program in asthma

Synergy begins phase IIa trial of SP-304 in patients with constipation

Takeda withdraws MAA for prolonged-release Competact for type 2 diabetes

PPD and Southern Research Institute collaborate on flu vaccine research services

OSI receives positive opinion on Tarceva for NSCLC from European health authorities

Agennix raises funds for continued talactoferrin development

AstraZeneca and Torrent Pharmaceuticals enter into branded generics agreement / News in Context

Helix BioPharma nears completion phase II trial of topical interferon alpha-2b for anogenital warts

Novel mu opioid receptor inverse agonist in phase I development by GSK for obesity

Roche submits MAA with EMA to extend MabThera label

FDA issues warning for highest approved dose of cholesterol-lowering Zocor

European orphan drug designation for Allon Therapeutics' davunetide in PSP

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...